RxDoctor Payments Data

Jennifer Avena, DO

Adult Medicine · Las Vegas, NVNPI 1578528998

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Pfizer at 33.8% of the total. 2023 is the largest year on record at $176, 3.1 times the $57 reported in 2019.

$350in general payments, 2019–2025

Across 19 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$118
  • ANI Pharmaceuticals, Inc.$65
  • Grifols USA, LLC$30
  • Baxter Healthcare$17
  • OPKO Pharmaceuticals, LLC$17
  • Abbott$17
  • plus $87 from 6 others

What the payments were for

  • Food & beverage$350100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few adult medicine providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$22,617
Medicare patients
51
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide15$32,495
OzempicSemaglutide13$26,061
XareltoRivaroxaban13$17,203
JardianceEmpagliflozin11$15,574
JanuviaSitagliptin Phosphate11$14,201
FarxigaDapagliflozin Propanediol18$13,913
Nurtec OdtRimegepant Sulfate12$11,515
Breo ElliptaFluticasone/Vilanterol16$6,108
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,193
Albuterol Sulfate HfaAlbuterol Sulfate50$2,117
Rosuvastatin Calcium141$1,945
Irbesartan64$1,914
Levothyroxine Sodium106$968
Atorvastatin Calcium130$879
Omeprazole64$604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$14$13,91318 claims
PfizerNurtec Odt$118$11,51512 claims
ANI Pharmaceuticals, Inc.Valsartan$65$18421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other adult medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →